Analysis of drug therapy of 53 patients with Corona Virus Disease-2019.

Objective: To explore safe and effective treatment strategies for the patients with Corona Virus Disease-2019 （COVID-19) Methods: The clinical data and treatment strategies of COVID-19 patients were collected and retrospectively analyzed Results: Major clinical manifestations of the patients with COVID-19 were fever (75 5% ) and cough (41 5%) Of the 53 COVID-19 patients, 42 were of common type, 6 were of severe type and 5 were of critical type Most of the critical type patients were the elderly with basic diseases Serum lymphocyte count decreased when they were admitted into hospital During hospitalization, C-reactive protein significantly increased in critical type patients Liver injury was observed in severe type and critical type patients With regard to treatment, 30 patients in the common type were treated with traditional Chinese medicine alone, 8 patients were treated with traditional Chinese medicine combined with lopinavir/ritonavir (LPV/r ), ２ patients were given traditional Chinese medicine combined with other drugs, and still another ２ patients were given interferon alone One severe type patient was treated with LPV/r combined with glucocorticoids, traditional Chinese medicine was given to other ５ severe type patients, including ２ patients with methylprednisolone sodium succinate combined treatment and one patient with interferon combined treatment The treatment of the critically ill patients was relatively complex, including antiviral, diuretic, cardiotonic treatment, as well as nutritional support Conclusion: Traditional Chinese medicine was beneficial to the recovery of COVID-19 patients However, definite benefits of combined treatment with LPV/r or glucocorticoids were not clearly observed (English) [ABSTRACT FROM AUTHOR] 探讨新型冠状病毒肺炎（Corona Virus Disease唱２０１９ ，COVID唱１９ ）患者安全 、有效的治疗方案 。 方法 ：采用 回顾性分析方法 ，收集和分析确诊为 COVID唱１９ 患者的临床资料和治疗方案 。 结果 ：COVID唱１９ 患者以发热（７５ ．５％ ）和咳嗽 咳痰（４１ ．５％ ）为主要症状 。 ５３ 例 COVID唱１９ 患者中普通型 ４２ 例 ，重型 ６ 例 ，危重型 ５ 例 。 危重型患者主要为合并基础疾病的 老年人 。 患者入院时淋巴细胞计数减少 ；危重型患者病程中 C唱反应蛋白明显升高 ，重型和危重型患者出现肝损伤 。 治疗方 面 ，普通型患者中 ３０ 例单一使用中药 ，８ 例使用中药联合洛匹那韦利托那韦（LPV／r） ，２ 例使用中药联合其他药物 ，２ 例仅使 用干扰素 ；重型患者除 １ 例使用 LPV／r 联合糖皮质激素类药物外 ，其余 ５ 例使用中药 ，其中联合使用甲泼尼龙琥珀酸钠 ２ 例 ， 联合使用干扰素 １ 例 ；危重型患者治疗较复杂 ，包括抗病毒 、利尿 、强心 、营养支持等 。 结论 ：中药治疗可能有助于 COVID唱１９ 患者病情恢复 ，但联合 LPV ／r 或糖皮质激素类药物治疗并未观察到明确的获益 。 (Chinese) [ABSTRACT FROM AUTHOR] Copyright of Pharmaceutial Care & Research is the property of Editorial Board of Pharmaceutial Care & Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )